Article PDF
Avoid common mistakes on your manuscript.
References
Alberts DS, Noel JK (1995) Cisplatin-associated neurotoxicity: can it be prevented? Anti-Cancer Drugs 6: 369–383
Chaudhry V, Rowinsky EJ, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304–311
Connelly B, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1996) Paclitaxel delivered as a 3 hour infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (in press)
McGuire WP, Hoskins WJ, Brady MF, Kucerta PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334: 1–6
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D (1994) Phase 1 trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241–248
Warner E (1995) Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 5: 161–169
Author information
Authors and Affiliations
Additional information
The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the authors
Rights and permissions
About this article
Cite this article
Markman, M. Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122, 511–512 (1996). https://doi.org/10.1007/BF01213547
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01213547